Could a common heart drug help dialysis patients?

NCT ID NCT07417215

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the drug sacubitril/valsartan can improve heart function in people with heart failure who are on chronic hemodialysis. 52 patients were split into two groups: one received the drug, the other standard care. Researchers measured changes in heart ultrasound and blood markers over 2 months to see if the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sacubitril/valsartan
What this could lead to
If it works, this could point toward a new treatment option for heart failure in people on dialysis, a group with few effective therapies.
What could go wrong
This is a small, early-phase study with only 52 participants and a short 2-month follow-up. The drug is not yet approved for dialysis patients, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE ON HEMODIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Clinical Hospital Mostar

    Mostar, 88000, Bosnia and Herzegovina

More trials for these conditions

Other studies related to the condition(s) this trial covers.